6.8 C
New York
Thursday, December 19, 2024
HomeUK NewsBritain’s health regulator backs COVID vaccine for infants from six months

Britain’s health regulator backs COVID vaccine for infants from six months

Date:

Related stories

Father and stepmother jailed for life over Sara Sharif’s murder

The father and stepmother of 10-year-old Sara Sharif, who...

Ban on cousin marriages suggested to combat forced marriages and protect public health

A leading academic has proposed banning marriages between first...

Questions raised over international action in Harshita Brella murder case

Authorities in the UK and India are under scrutiny...

Sara Sharif: Harrowing details of abuse revealed in court

Ten-year-old Sara Sharif was found dead in her Woking...

 

Britain’s health regulator on Tuesday authorised a COVID-19 vaccine for infants as young as six months, opening the door for vaccinating the country’s youngest children once the UK’s Joint Committee on Vaccination and Immunisation (JCVI) agrees.

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised the vaccine – made by Pfizer PFE.N and BioNTech 22UAy.DE – for children aged six months to four years old, after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.

Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be used as part of the national vaccination programme.

The vaccine is tailored for use in this age group – it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.

- Advertisement -

 

U.S. officials rolled out this version of the Pfizer-BioNTech shot for the same age group earlier this year. Months ago, EU regulators also endorsed the use of COVID vaccines made by Pfizer-BioNTech and Moderna mRNA.For under-fives.

(Reuters)

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories